LEQEMBI, LECANEMAB AUTOINJECTOR

LEQEMBI is a prescription medication specifically designed for the treatment of Alzheimer's disease in adults. It is intended for patients who are in the early stages of the disease, such as those with mild cognitive impairment or mild dementia. The primary function of this drug is to target and reduce the accumulation of amyloid beta plaques in the brain, which are protein clusters believed to play a significant role in the progression of the condition. By reducing these plaques, the medication aims to slow the decline in cognitive and daily functioning. This monoclonal antibody therapy is administered via intravenous (IV) infusion. It works by identifying and binding to specific forms of amyloid beta to help the body clear them from brain tissue. Before starting the medication, healthcare providers must confirm the presence of amyloid plaques through diagnostic testing. This treatment is part of a therapeutic class focused on modifying the underlying biological processes of Alzheimer's rather than just managing symptoms temporarily.